Esomeprazole Versus Pantoprazole to Prevent Peptic Ulcer Rebleeding

• Status: Withdrawn
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to compare the clinical effectiveness of intravenous esomeprazole and pantoprazole in preventing recurrent bleeding in the patients with high-risk bleeding peptic ulcers after successful standard endoscopic hemostasis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Lotung Poh-Ai Hospital
• Collaborator: Tomorrow Medical Foundation
• Treatments: Esomeprazole; Pantoprazole

Criteria

Inclusion Criteria:

• aged more than 18 years

• undergo emergent endoscopy within 24 hours of presentation

• have peptic ulcers in the gastroesophageal junction, stomach, or duodenum

• high-risk stigmata of peptic ulcers: Forrest classification IA~IIB

• endoscopic hemostasis by thermocoagulation or clip placement

Exclusion Criteria:

• pregnant or lactating

• written informed consent not obtained

• initial endoscopic hemostasis fail

• bleeding tendency (platelet count < 50×109/L, prolonged prothrombin time for more than 3 seconds, or were taking anticoagulants)

• PPI use within 14 days of enrollment

• comorbid with severe hepatic or renal insufficiency (serum total bilirubin more than 5 mg/dL, serum creatinine more than 5 mg/dL, or under dialysis)

• bleeding gastric cancers